Targin is commonly used across two distinct therapeutic domains, which are aligned with its official indications. A specific secondary indication is relevant for easing symptoms associated with heightened neurological or muscular activity.

This medication is applied in clinical settings that involve continuous symptomatic relief for severe persistent pain, and is used for managing Opioid-Induced Gastrointestinal Dysfunction related to reduced bowel function. It is also applied in situations involving recurrent or episodic manifestations, such as severe to very severe idiopathic restless legs syndrome (RLS).

“The primary benefit provides support that helps ease the overall symptom burden while assisting with maintaining functional stability.”

---

Continuous Relief for Symptom Domains

For symptoms related to physical discomfort, the benefit helps improve day-to-day comfort during symptomatic periods and supports the patient with sustained analgesic support. For symptoms linked to organ-specific functional stress, the feature assists with maintaining functional stability and supports patients during episodes of heightened discomfort. For symptoms of increased neurological or muscular activity (RLS), it helps ease the overall symptom load.

---

Quick Fact: Relief for Co-Occurring Symptoms The formulation is commonly used to help address symptom clusters that may become intense or disruptive, specifically severe physical discomfort and gastrointestinal symptoms.

Regulatory References

1. Health Products Regulatory Authority (HPRA) product information

Eligibility Map: Who Can and Cannot Use Targin (Oral) — Official Regulatory Information

Official regulatory documents define the eligibility for Targin (Oral) by establishing the medicine for use in adults (age 18 and older) who require continuous, around-the-clock strong opioid treatment. Use in other populations is strictly limited or prohibited based on specific health conditions or age status.

---

Absolute Contraindications (Must Not Use)

The medicine is contraindicated (absolutely prohibited) for patients with the following conditions or statuses, as documented in official labeling:

• Respiratory Compromise: Significant respiratory depression, severe bronchial asthma, Cor Pulmonale, or Chronic Obstructive Pulmonary Disease (COPD).
• Gastrointestinal Issues: Known or suspected paralytic ileus or other gastrointestinal obstructions.
• Liver Function: Moderate to severe hepatic impairment.
• Other: Acute opioid withdrawal, or known hypersensitivity to oxycodone or naloxone.

---

Age and Conditional Restrictions

Population Group	Official Eligibility Status
Children and Adolescents (Under 18)	Contraindicated; safety and efficacy are Not Established
Severe Renal Impairment (CrCl < 30 mL/min)	Not Recommended; requires extreme caution
Mild Hepatic Impairment	Use with caution; requires a reduced initial dose
Pregnancy	Not Recommended
Breastfeeding (Lactation)	Contraindicated

Eligibility is fundamentally structured around preventing use in individuals with pre-existing, severe respiratory or organ dysfunction, and excluding pediatric and breastfeeding populations.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Targin based on pharmacokinetic and pharmacodynamic mechanisms. Co-administration with CYP3A4 inhibitors results in an increase in the plasma concentration (exposure) of Oxycodone. Conversely, co-administration with CYP3A4 inducers decreases Oxycodone exposure.

Interaction Type	Interacting Substance/Class	Official Regulatory Outcome
Contraindicated Combination	Monoamine Oxidase Inhibitors (MAOIs)	Potential for potentiation of opioid effects; must not be used within 14 days of stopping MAOIs.
Pharmacodynamic Reinforcement	CNS Depressants (e.g., Sedatives, Opioids)	Additive effect leading to profound sedation and respiratory depression.
Pharmacokinetic Risk	Alcohol (Ethanol)	Prohibition of use due to risk of rapid release (dose dumping) of Oxycodone.

This medicine is also formally contraindicated for patients with moderate to severe hepatic impairment due to the altered clearance and systemic exposure profile. Interactions with food are documented, as administration with a high-fat meal results in a documented increase in the peak plasma concentration ( C max) and total exposure ( AUC) of Oxycodone. Co-administration with mixed agonist/antagonist opioid analgesics is noted to potentially reduce the analgesic effect.

The drug's mechanism involves the fixed-dose combination of an opioid agonist and an antagonist, whose actions are spatially separated.

Central mu-Opioid Agonism for Signal Dampening

The core mechanism of oxycodone involves full agonism at mu-opioid receptors (MOR) primarily within the central nervous system (CNS). This binding activates a G-protein cascade that stabilizes and hyperpolarizes nerve cells, modifying the early molecular steps that shape systemic physiological outcomes. This dampening of the nociceptive signaling pathway leads to a reduction in the transmission of incoming pain signals.

Peripheral mu-Opioid Antagonism for Motility Counteraction

The co-formulated naloxone functions as a competitive antagonist, acting almost exclusively on mu-opioid receptors located in the wall of the gastrointestinal (GI) tract. Due to extensive first-pass metabolism after oral dosing, the systemic concentration of naloxone is kept low, localizing its blocking action to the gut. This mechanism directly prevents oxycodone from binding to peripheral receptors, thereby counteracting the opioid-mediated reduction in autonomic smooth muscle tone and rhythmic movement (peristalsis).

Functional Decoupling and Mechanistic Synergy

The combination achieves mechanistic synergy by functionally decoupling the primary analgesic action (central effect) from the motility-reducing action (peripheral effect). The two components engage opposite mechanisms on the same receptor class, but in physically separate compartments, ensuring that the CNS action proceeds uninterrupted while the GI pathway's motility-reducing action is counteracted.

Official Dosing and Administration

Targin is a prolonged-release tablet used only via the oral route. The administration of this medicine is based on official instructions to ensure the intended therapeutic delivery over a sustained period.

Standard Adult Dosing and Frequency

Regimen Element	Official Instruction
Starting Dose	Typically 10 mg/5 mg (Oxycodone/Naloxone) twice daily.
Dosing Frequency	Must be taken on a fixed time schedule twice daily (every 12 hours).
Dose Titration	Dosage may be adjusted, usually in steps of 5 mg/2.5 mg twice daily, every 1–2 days.
Maximum Dose	General maintenance dose does not typically exceed 40 mg/20 mg daily.

Key Administration Requirements

To maintain the intended prolonged-release properties, the tablets must be swallowed whole with sufficient liquid. It is strictly forbidden to divide, break, chew, crush, or dissolve the tablets prior to intake. Targin can be taken with or without food as the timing relative to meals is not restricted by regulatory guidelines.

If a dose is missed, it should only be taken if the next dose is more than 8 hours away, and under no circumstances should a double dose be taken to compensate.

Population-Specific Instructions

Official labeling indicates that dose adjustments are necessary for certain populations. For patients with mild hepatic impairment, for instance, the recommended starting dose is one-third to one-half the usual initial dose. Caution and frequent monitoring are also advised when administering Targin to older adults and patients with renal impairment.

Targin (Oxycodone/Naloxone) Clinical Evidence Overview

Clinical research has centered on the dual effects of Targin prolonged-release tablets: pain relief from the oxycodone component and mitigation of opioid-induced constipation (OIC) from the naloxone component. The naloxone acts locally in the gut to block opioid receptors, while its low absorption is intended to maintain the analgesic effect of oxycodone in the central nervous system.

---

Efficacy in Chronic Pain

Multiple randomized, double-blind, Phase III trials involving patients with chronic non-cancer pain (CNCP) have evaluated Targin. These studies reported that Targin provided pain relief comparable to that of oxycodone prolonged-release tablets alone over 12 weeks. Analgesic efficacy was measured using validated pain scales, with results indicating similar sustained reductions in pain intensity for both medications.

Bowel Function and OIC Mitigation

The primary distinguishing finding in the clinical evidence is the effect on bowel function. Across pivotal trials, Targin demonstrated statistically significant improvements in bowel function, as measured by the Bowel Function Index (BFI), compared to oxycodone alone. Studies reported lower rates of constipation and reduced need for laxative use in patients taking the oxycodone/naloxone combination.

Study Focus	Primary Finding (Targin vs. Oxycodone PR)
Analgesia	Comparable sustained pain relief
Bowel Function	Statistically significant improvement in BFI scores

---

Long-term and Specific Indications

Long-term open-label extension studies, lasting up to 52 weeks, were conducted to examine the sustained effects and tolerability of Targin. These trials reported that the benefits in pain control and bowel function were generally maintained over the extended period. Targin has also been the subject of research for the symptomatic treatment of severe to very severe Restless Legs Syndrome (RLS) in patients who have not responded adequately to certain other therapies. These trials reported a reduction in the severity of RLS symptoms.

Common questions about Targin (Oral) (FAQ)

---

Q: Does Targin interact with common over-the-counter pain relievers?

Official regulatory labeling cautions against taking Targin with other Central Nervous System (CNS) depressants. This group can include certain over-the-counter medicines such as sedating cold or allergy products that contain antihistamines. The label indicates that patients should review all co-administered medicines with a healthcare provider to understand potential interactions.

---

Q: What are the guidelines concerning Targin use for individuals with a history of substance abuse?

Regulatory documents clearly emphasize the potential risks of addiction, abuse, and misuse associated with this medication. Official labeling highlights the need for caution and careful monitoring when this medication is used by individuals with a known history of substance abuse or mental health conditions.

---

Q: Does Targin contain any other active or inactive ingredients besides oxycodone and naloxone?

Yes, official product descriptions list both the active ingredients, oxycodone and naloxone, and the inactive ingredients. These inactive components typically include standard tablet materials such as binding agents, fillers, and coating substances necessary for the prolonged-release formulation.

---

Q: What is the standard procedure for stopping Targin treatment as described in patient information?

Regulatory documents advise that when this medication is no longer needed, the dosage should be gradually reduced over time. Sudden cessation can lead to symptoms of withdrawal (known as abstinence syndrome). Therefore, a gradual reduction is the standard approach to minimize this risk.

---

Q: Is Targin ever used for acute post-operative pain?

According to official labeling, Targin is indicated for the treatment of severe chronic pain that requires continuous, around-the-clock opioid management. It is not indicated for the management of acute pain, such as pain experienced immediately following a surgical procedure.

---

Q: How does Targin compare to a morphine-based pain reliever in its description of use?

Targin contains oxycodone, which is classified in regulatory sources as a strong opioid analgesic. This places it in the same general pharmacological class for pain relief as morphine. Official documentation only describes Targin's use and safety profile and avoids making comparative claims regarding efficacy or superiority against other medicines.

---

Q: Does Targin cause mood changes or affect mental health?

Official documents list psychiatric disorders as potential adverse reactions associated with Targin. These can include mood-related symptoms such as anxiety, insomnia, or nervousness, and they also note the potential for euphoria.

---

Q: What is the role of Targin in palliative care?

Targin is indicated for the treatment of severe pain, a need that is central to palliative care. Its official purpose is for pain requiring continuous opioid management, which makes it a potential treatment option in this setting based on its defined indication.

---

Q: Can Targin affect my ability to drive or operate heavy machinery?

Official labeling includes a specific warning that this medicine may impair a person’s ability to drive or operate heavy machinery. This potential risk is noted as being highest when the treatment is started, following any dose adjustment, or when the medicine is used in combination with alcohol or other sedating medicines.

---

Q: What are the signs of an allergic reaction to Targin?

Regulatory documents note that known hypersensitivity (a severe allergic-type reaction) is a contraindication to using Targin. Official documentation notes adverse reactions such as rash, pruritus (itching), or urticaria (hives), which may be indicative of a sensitivity or allergic-type response.

---

Q: What is the official guidance on managing breakthrough pain while taking Targin?

Official labeling states that Targin is not indicated for the management of breakthrough pain, which is temporary pain that occurs despite continuous opioid treatment. Official documents state that Targin is not indicated for breakthrough pain, and patients generally require a separate, immediate-release opioid medication to manage such pain.

---

Q: Does Targin affect my heart rate or blood pressure?

Official documents list cardiovascular adverse effects associated with Targin. These can include changes to the blood vessels resulting in hypotension (low blood pressure), and effects on heart rhythm such as tachycardia (rapid heart rate) or bradycardia (slow heart rate).

---

Q: Are there different strengths of Targin available?

Yes, official labeling confirms that Targin is available in a range of fixed-dose strengths. These strengths are typically found in various increments of the oxycodone/naloxone combination, such as 5 mg/2.5 mg up to 40 mg/20 mg tablets.

---

Q: What is the risk of tolerance development with Targin according to research?

Official documents discuss the development of tolerance as a characteristic of opioid analgesics. This means that, over time, a patient may require increasing doses to maintain the same level of pain control. This is a common physiological effect described in the regulatory information.

---

Q: What if I vomit or throw up right after taking a dose of Targin?

Official guidance for Targin, a fixed-schedule, prolonged-release medicine, follows the missed dose instructions. Due to its prolonged-release formulation and fixed schedule, taking a replacement dose immediately could risk an unintended dose increase. Therefore, the general principle of avoiding a replacement dose if the next one is close is applied.

Storage and Disposal Requirements

Official labeling defines specific conditions for storing Targin tablets to maintain product stability and ensure public safety. The medication must be kept at room temperature, generally defined as below 25°C, and must be protected from moisture, heat, and direct light; freezing is prohibited. The tablets must remain in the original blister pack and a closed container until use.

Child Safety and Disposal

Due to the severe risk of accidental fatal overdose, Targin must be kept out of the sight and reach of children, ideally secured in a locked cabinet.

Unused or expired tablets should be promptly discarded via a drug take-back program. If a take-back option is unavailable, the product is listed as a medication that should be immediately flushed down the toilet to prevent accidental poisoning.